Navigation Links
Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
Date:8/19/2007

Oncomine and Oncomine Concepts Map Integral in Expression and Association

Analyses

ANN ARBOR, Mich., Aug. 2 /PRNewswire/ -- Building on an earlier study that used Oncomine(TM) to identify ETS-fusion proteins in prostate cancer (Science, Oct 28 2005), Tomlins et al. today report the identification of four additional classes of ETS rearrangements in prostate cancer, each of which activates ETV1 by a different genetic mechanism (Nature, Aug 2 2007).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

Tomlins et al. queried the Oncomine database to determine the tissue specificity of three of the new fusion gene partners, demonstrating that two new partners are prostate cancer specific while the third partner is a generally over-expressed 'house-keeping' gene. In addition, Oncomine Concepts Map was applied to test for similarities between the set of genes regulated by ETV1 with sets of genes related to other biological concepts. This analysis revealed a clear association between ETV1 activation and cellular invasion, a hallmark of cancer.

Oncomine, a dynamic repository that combines rich data, sophisticated analysis, and responsive user interface, empowers oncology research by bringing data analysis tools to a large cancer gene expression database, which includes data from 20,000+ microarray experiments curated from 300+ independent studies. Oncomine Concepts Map, an extension of Oncomine, is a compilation of nearly 8,000 Oncomine cancer gene signatures together with 11,500 gene, protein, drug, and pathway signatures collected from the literature and other public sources.

"This study marks an important advance in our understanding of the molecular basis of prostate cancer. Oncomine again proved invaluable in examining the expression of genes in cancer, and in this case aided in the characterization of new sub-types of prostate cancer," said Dan Rhodes, Ph.D., co-founder and Chief Science Officer of Compendia Bioscience. "The authors went on to show that one of the new subtypes is unlikely to respond to conventional anti-androgen therapy, and another may be adversely affected by standard therapies. This strongly suggests that using this type of molecular information to distinguish patient populations will have important clinical implications."

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes.

About Oncomine(TM)

Oncomine(TM) combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.

About Oncomine(TM) Concepts Map

Oncomine Concepts Map is licensed to commercial users as part of the Oncomine Concepts Edition and the Oncomine Enterprise Edition. Visit http://www.compendiabio.com for more information. An academic preview edition is available to academic and non-profit researchers at http://www.oncomine.org.


'/>"/>
SOURCE Compendia Bioscience, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Protox Announces Positive Clinical Data from Prostate Cancer Study
4. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
5. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
6. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
7. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
8. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
9. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
10. Quest PharmaTechs Prostate Cancer Program Update
11. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):